Key Clinical Message
Treatment of mCRPC resistant to ARATs is a clinical challenge. Docetaxel could significantly improve the survival of these patients. However, when resistance to taxane-based chemotherapy develops, treatment options are limited. Administration of supraphysiological doses of testosterone might re-sensitize cancer cells to various treatment modalities including hormonal and chemotherapy.